Overview

Several blood-based biomarkers are being studied for mesothelioma detection. While no blood test can definitively diagnose mesothelioma, these tests can support diagnosis and help monitor disease progression or treatment response.

Why This Matters

Biomarker testing is becoming increasingly valuable for early detection efforts, monitoring treatment effectiveness, and potentially screening high-risk individuals in the future.

Procedures and Tests

SMRP (Mesothelin)

Soluble mesothelin-related peptides are elevated in many mesothelioma patients. FDA-approved for monitoring treatment response.

Most widely used mesothelioma biomarker

Osteopontin

A protein found at higher levels in mesothelioma patients. May help distinguish malignant from benign pleural disease.

Research stage

Fibulin-3

A newer biomarker showing promise for early detection. May be detectable in both blood and pleural fluid.

Newer biomarker under study

MPF (Megakaryocyte Potentiating Factor)

Another protein related to mesothelin that may be elevated in mesothelioma.

Often used with SMRP

Complete Blood Count

General blood work to assess overall health and detect anemia or other abnormalities.

Part of standard workup

What to Expect

  • Simple blood draw from arm vein
  • No special preparation typically required
  • Results usually available within days
  • May be repeated to track changes over time
  • Often combined with imaging and other tests

Advantages

  • Non-invasive and low-risk
  • Can monitor treatment response
  • May aid early detection research
  • Useful for ongoing surveillance

Limitations

  • Cannot provide definitive diagnosis
  • Elevated levels can occur in other conditions
  • Not all mesotheliomas produce detectable biomarkers
  • May miss early-stage disease

Next Steps After Diagnosis

Once mesothelioma is confirmed, your medical team will work to determine the stage of the disease and develop a treatment plan. This typically involves:

  • Additional imaging to assess cancer spread
  • Consultation with mesothelioma specialists
  • Discussion of treatment options based on cell type and stage
  • Consideration of clinical trial eligibility
Learn about staging → Explore treatment options →